Galapagos gives R&D update

  • Competitive positioning and Phase II study plans in RA for GLPG0634
  • Excellent First-in-Human results with GLPG0974 targeting GPR43
  • Phase I Proof of Mechanism results of GLPG0492
  • Novel antibody shows in vivo Proof of Concept for inflammatory disorders
  • New class of compounds discovered in antibacterials
  • Dr Piet Wigerinck named Chief Scientific Officer

Webcast presentation today at 12.30 CET/6:30am ET on
US +1-877-941-6009; Belgium +32-2290-1608; Netherlands +31 20 794 8504

Mechelen, Belgium; 18 April 2012 – Galapagos NV (Euronext: GLPG) will give an R&D Update later today, indicating progress and plans for its large portfolio of more than 50 research programs.  In addition to laying out the competitive positioning and Phase II plans for selective JAK1 inhibitor GLPG0634 in rheumatoid arthritis, a number of other topics will be discussed, including:

Excellent First-in-Human results with GLPG0974
GLPG0974 is an orally available small molecule that reduces migration of neutrophils, one of the critical cell types in inflammatory processes, by potent inhibition of GPR43 (also known as FFAR2).  Overactivity of neutrophils is a cause of tissue damage in illnesses such as inflammatory bowel disease, and this anti-inflammatory mechanism may provide for a novel treatment approach.  GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically.  In this First-in-Human study, healthy volunteers were given increasing single doses of candidate drug GLPG0974 by oral administration.  Encouraging safety data showed no relevant safety findings, including adverse events, changes in vital signs or laboratory parameters.  The favourable PK profile and the highly significant changes in neutrophil biomarkers are consistent with once- or twice-daily oral dosing.  Galapagos intends to complete Phase I studies and determine the Phase II clinical strategy before year end 2012.

Phase I Proof of Mechanism results of GLPG0492
GLPG0492 is an orally available selective androgen receptor modulator (SARM) which was tested in a Phase I Proof of Mechanism study to assess the effect on muscle function in healthy volunteers.  A biomarker effect similar to that of Oxandrolone was observed, but the data were insufficient for Galapagos to pursue GLPG0492 further in cachexia.  With the financial support of Charley’s Fund and the Nash Avery Foundation, improvement of muscle strength and running performance in a pre-clinical model of Duchenne muscular dystrophy (DMD) was shown with GLPG0492 in 2011.  Galapagos intends to discuss with these patient organizations the opportunity for them to develop GLPG0492 further in DMD.

Novel antibody shows in vivo Proof of Concept for inflammatory disorders
In November 2008, Galapagos and MorphoSys entered an antibody alliance aimed at discovering and developing antibody therapies based on novel modes of action in the area of immuno-inflammation disorders.  Neutralizing antibodies with high specificity towards this target have now been tested in two gold standard, disease-specific in vivo models – rheumatoid arthritis and COPD – and achieved positive Proof of Concept.  A joint program for generation of a fully human antibody directed against this target has now been initiated.  Pre-clinical candidate selection could be achieved by mid 2013.

New class of compounds discovered in anti-infectives
In the alliance with GSK in anti-infectives, Galapagos discovered a new class of compounds with a novel mode-of-action by inhibiting DNA polymerase III, an enzyme essential for bacterial DNA replication.  The compounds show activity in different MRSA in vivo models and thus may offer a new approach to treat resistant S. Aureus strains, with potential for broader spectrum application.  GSK and Galapagos have ended the anti-infectives alliance, and all assets have been returned to Galapagos, including the DNA polymerase III mode-of-action programs.

Appointment of Piet Wigerinck as CSO
Dr Piet Wigerinck has been named Chief Scientific Officer, responsible for all research and development activities at Galapagos.  Dr Wigerinck joined Galapagos as Senior Vice President Development in April 2008, and was responsible for the successful Proof-of-Concept study with selective JAK1 inhibitor GLPG0634.  As CSO, Dr Wigerinck will oversee target and drug discovery efforts, in addition to expanding Galapagos’ development department to deliver the Phase II study data package with GLPG0634.  Prior to joining Galapagos, Dr Wigerinck was VP Drug Discovery, Early Development and CM&C, and a member of the Management Board at Tibotec (a subsidiary of Johnson & Johnson), where he played a key role in Tibotec’s expansion into novel diseases such as Hepatitis C and advanced several compounds into Phase I and Phase II clinical trials, including Prezista®.

Webcast presentation
Galapagos will hold an audio webcast presentation for journalists, analysts, and investors today at 12:30 pm CET/6:30 am Eastern US, viewable at

Call numbers:
Belgium                        0800 50747
Netherlands                   0800 265 8528
US                                1-877-941-6009
Other countries              +32 2290 1608 or +31 20 794 8504

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action.  The Company is progressing GLPG0634, as well as one of the largest pipelines in biotech, with four programs in development and over 50 discovery programs.  The Galapagos Group has about 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More info at:


Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.